Video
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).
Transcript
What does the treatment paradigm for pediatric MS look like today?
That's a good question, but we have the recommendation from the international multiple sclerosis group that disease-modifying treatment should be initiated in children with MS. Of course, the benefit/risk should be also taken into consideration, so the treatment paradigm in most of the countries is escalation therapy, starting with a mild, moderately effective drug in mild and moderate diseases activity. But I see in our registry and also in others that children with highly active disease are initiated with more effective therapies.
Evaluating COVID-19 Vaccination Safety in Multiple Sclerosis
Expert Insights on How Utilization Management Drives Physician Burnout
Researchers Outline Promising Biomarkers Throughout Course of MS